SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 197 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 1.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $26,322,669 | +51.6% | 238,128 | +2.8% | 0.22% | +51.7% |
| Q2 2022 | $17,362,160 | -1.6% | 231,619 | +2.5% | 0.14% | +30.6% |
| Q1 2022 | $17,651,370 | -41.2% | 225,952 | -32.3% | 0.11% | -36.9% |
| Q4 2021 | $30,041,671 | +1616.8% | 333,611 | +1382.1% | 0.18% | +1500.0% |
| Q2 2021 | $1,749,850 | -7.0% | 22,509 | -10.8% | 0.01% | -31.2% |
| Q1 2021 | $1,880,616 | -72.8% | 25,233 | -37.7% | 0.02% | -70.9% |
| Q4 2020 | $6,903,481 | +102.3% | 40,492 | +66.6% | 0.06% | +44.7% |
| Q3 2020 | $3,413,000 | -13.0% | 24,309 | -0.7% | 0.04% | -17.4% |
| Q2 2020 | $3,924,000 | +49.6% | 24,472 | -8.7% | 0.05% | +58.6% |
| Q1 2020 | $2,623,000 | -74.5% | 26,810 | -66.4% | 0.03% | -63.8% |
| Q4 2019 | $10,300,000 | -69.1% | 79,822 | -82.0% | 0.08% | -69.1% |
| Q3 2019 | $33,370,000 | -3.6% | 443,054 | +94.4% | 0.26% | +2.4% |
| Q2 2019 | $34,633,000 | -0.0% | 227,917 | -21.6% | 0.25% | -11.5% |
| Q1 2019 | $34,642,000 | +398.3% | 290,645 | +356.3% | 0.29% | +410.7% |
| Q4 2018 | $6,952,000 | -20.1% | 63,697 | +18.3% | 0.06% | -1.8% |
| Q3 2018 | $8,699,000 | -47.5% | 53,859 | -57.0% | 0.06% | -38.7% |
| Q2 2018 | $16,555,000 | +219.9% | 125,250 | +34.7% | 0.09% | +287.5% |
| Q4 2017 | $5,175,000 | +115.6% | 93,000 | +75.8% | 0.02% | +50.0% |
| Q3 2017 | $2,400,000 | -0.7% | 52,900 | -26.2% | 0.02% | 0.0% |
| Q2 2017 | $2,417,000 | -74.4% | 71,700 | -77.5% | 0.02% | -77.1% |
| Q1 2017 | $9,427,000 | -85.4% | 318,500 | -86.5% | 0.07% | -80.6% |
| Q4 2016 | $64,527,000 | -80.1% | 2,352,442 | -55.5% | 0.36% | -78.4% |
| Q3 2016 | $324,982,000 | +171.9% | 5,292,014 | -15.6% | 1.68% | +209.0% |
| Q2 2016 | $119,507,000 | +144.7% | 6,266,729 | +150.4% | 0.54% | +92.9% |
| Q1 2016 | $48,848,000 | +513.1% | 2,502,479 | +1111.9% | 0.28% | +524.4% |
| Q4 2015 | $7,967,000 | -21.3% | 206,500 | -34.5% | 0.04% | -22.4% |
| Q3 2015 | $10,117,000 | +74.0% | 315,043 | +64.9% | 0.06% | +93.3% |
| Q2 2015 | $5,815,000 | +938.4% | 191,100 | +352.8% | 0.03% | +900.0% |
| Q1 2015 | $560,000 | -94.3% | 42,203 | -93.8% | 0.00% | -94.8% |
| Q4 2014 | $9,798,000 | -28.2% | 677,129 | +4.6% | 0.06% | -38.3% |
| Q3 2014 | $13,654,000 | -52.1% | 647,106 | -32.3% | 0.09% | -61.0% |
| Q2 2014 | $28,483,000 | -20.1% | 956,110 | -35.5% | 0.24% | -30.5% |
| Q1 2014 | $35,636,000 | -23.0% | 1,482,999 | -34.7% | 0.35% | +17.6% |
| Q4 2013 | $46,256,000 | -45.8% | 2,270,762 | +25.6% | 0.30% | -64.7% |
| Q3 2013 | $85,362,000 | +71.4% | 1,807,371 | +38.0% | 0.84% | +56.4% |
| Q2 2013 | $49,798,000 | – | 1,309,439 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |